Please select the eligibility criteria that correspond to the clinical trial below.
Title: Low Vision Depression Prevention Trial for Age Related Macular Degeneration
Brief Summary: This randomized, controlled clinical trial, the Low Vision Depression Prevention TriAL (VITAL), will test the efficacy of collaborative low vision rehabilitation (LVR) to prevent depressive disorders in Age-Related Macular Degeneration (AMD). In this innovative intervention, a low vision occupational therapist collaborates with a low vision optometrist to develop and implement a care plan based on a subject's vision status, rehabilitation potential, and personal rehabilitation goals. An independent rater masked to treatment assignment will assess depressive disorders meeting DSM-IV criteria (primary outcome) and targeted vision function and vision-related quality of life (secondary outcomes) at baseline and then at 4 months to evaluate short-term effects (main trial end point) and at 12 months to evaluate long-term effects.


Options:
A: Inclusion Criteria:

* Age at least 65 years old
* Bilateral AMD
* Subthreshold depressive symptoms
* At least 1 vision goal that is important yet difficult to carry out

Exclusion Criteria:

* Uncontrolled glaucoma, diabetic retinopathy, corneal dystrophy, or cataracts for which surgery within 6 months is likely will be exclusionary conditions
* Current diagnosis of depression
* Cognitive impairment
* Life-threatening illness or any other health conditions that interferes with study activities.
* Patients who have received low vision rehabilitation or home-based OT in the preceding 12 months will be excluded.
B: Inclusion Criteria:

* Primary eye diagnosis (better seeing Eye) macular disease
* Best-corrected visual acuity (better seeing eye) 20/50-20/200

Exclusion Criteria:

* Does not have a telephone
* Does not speak English
* Has received interdisciplinary low vision services
* English literacy less that 5th grade reading level
* Failed TICS
* Unable or unwilling to attend required clinic visits
* Severe hearing impairment preventing administration of telephone questionnaires
* Planned cataract extraction in next 4 months
* Visual fields contracted to diameter of 20 degrees in better-seeing eye
* Vitreous hemorrhage or serous hemorrhagic detachment of macula
* CNVM treated with fewer than 3 anti-VEGF injections
* Diabetic macular edema (DME) treated with focal/grid laser within the last two months
* DME treated with intravitreal injections of anti-VEGF or intravitreal triamcinolone acetonide (IVTA) within the last two months
* Cystoid macular edema (CME) treated with topical (non-steroidal anti-inflammatory drugs) NSAIDS, topical steroids or IVTA within the last three months
C: Inclusion Criteria:

* Definite Optic Neuritis within 60-180 Days or \< 12 months before Screening
* Visus \> 0.05
* Visus \< 0.7 or confirmed visual field deficit
* Ability to give Informed Consent

Exclusion Criteria:

* Systemic Treatment with Glucocorticosteroids within 30 days prior to Screening
* Additional significant ophthalmological disease
* Pregnancy
* History of Epilepsy
* Significant arterial Hypertension
D: Inclusion Criteria:

* Visual acuity impairment
* Diabetic macular edema in at least one eye
* Type 1 or type 2 diabetes mellitus
* Medication for the diabetes treatment must be stable for the last 3 months

Exclusion Criteria:

* Patients with uncontrolled systemic or ocular diseases
* Laser photocoagulation in the study eye for the last 3 months
* Any history of any intraocular surgery in the study eye within the past 3 months
* Blood pressure \> 160/100 mmHg

Extension Inclusion Criteria:

-Completion of the Core Study

Answer: A